Antimicrobial Susceptibility Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Manual Antimicrobial Susceptibility Testing Product (Susceptibility Testing Disks, MIC Strips, and Susceptibility Testing Plates), Automated Laboratory Instruments, Culture and Growth Media, and Consumables)), By Type (Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing, and Other Susceptibility Testing Types (slow-growing pathogens), By Method (Etest Method, Disk Diffusion, Automated Susceptibility Testing Instruments, Agar Dilution, Genotyping Methods), By Application Type (Clinical Diagnostics, Drug Discovery and Development, Epidemiology, and Other Applications (Research and academic applications, bioterrorism surveillance, and environmental monitoring)), By End User (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research & Academic Institutes, and Clinical Research Organizations (CROs)), and Region  

Antimicrobial Susceptibility Testing Market size was valued at US$ 3,645.3 million in 2023 and is projected to grow at a 6.2% CAGR from 2024 to 2030. Antimicrobial susceptibility testing (AST) is a laboratory procedure to identify an accurate antimicrobial regimen against microbes. AST of the connective agent(s) is essential for judiciously selecting appropriate antimicrobial therapy. The market is primarily driven by the increasing number of pathogenic bacteria gaining antibiotic resistance and new forms of resistance are steadily emerging, which enable clinicians to execute antimicrobial susceptibility testing (AST) with urgency. A rapid multiplexed AST platform delivers minimum inhibitory concentrations (MICs) within hours at a feasible cost, which empowers rapid determination of effective targeted bacteriophage therapy, ensuing in short hospital stays, and fewer laboratory tests, decreasing morbidity and mortality along with their healthcare expenses. These advancements in the healthcare sector further enhance.

Furthermore, the increasing number of new launches of products based on various technologies is expected to push the market growth. For instance, the CE-marked Alfred 60 AST system of Alifax S.r.l. Italy, a company specializing in the development, production, and distribution of automated clinical diagnostic instruments, practices sensitive laser-light scattering technology to detect bacterial growth in a liquid culture broth and provides antimicrobial susceptibility results directly from positive blood culture bottles within 4-6 hours. Furthermore, in 2018, Beckman Coulter Inc., a subsidiary of Danaher, announced the commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial detection and antibiotic susceptibility testing for microbiology research laboratories.

Key Developments

In February 2020, Bio-Rad Laboratories, Inc., a global company engaged in developing, manufacturing, and marketing an extensive range of innovative products for the life science research and clinical diagnostic markets, developed Exact Diagnostics.